These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8877676)

  • 41. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
    Julian DG; Camm AJ; Frangin G; Janse MJ; Munoz A; Schwartz PJ; Simon P
    Lancet; 1997 Mar; 349(9053):667-74. PubMed ID: 9078197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amiodarone and sustained ventricular arrhythmias: statistical evidence of drug effectiveness.
    Flaker GC; Alpert MA; Webel RR; Ruder MA; Sanfelippo JF; Tsutakawa RK
    Am Heart J; 1985 Aug; 110(2):371-6. PubMed ID: 4025112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Amiodarone-induced thyroid gland dysfunctions].
    Gassanov N; Dietlein M; Caglayan E; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Apr; 135(16):807-11. PubMed ID: 20391312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals].
    Gaete LE; Ortiz M; Soto J; Saavedra I
    Rev Med Chil; 1995 Jun; 123(6):713-9. PubMed ID: 8525224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of the antifibrillatory effects of desethylamiodarone to amiodarone in a swine model.
    Zhou L; White CM; Chen BP; Chow MS; Fan C; Kluger J
    J Cardiovasc Pharmacol; 1999 Sep; 34(3):440-5. PubMed ID: 10471005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of chronic amiodarone therapy on left ventricular function in dilated cardiomyopathy studied by the new Doppler-index].
    Lengyel M
    Orv Hetil; 1998 May; 139(19):1147-51. PubMed ID: 9613163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of CYP1A induction on amiodarone disposition in the rat.
    Elsherbiny ME; Brocks DR
    J Pharm Sci; 2010 Jan; 99(1):539-48. PubMed ID: 19718765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of neferine on the pharmacokinetics of amiodarone in rats.
    Wan J; Zhao L; Xu C; Zhang S; Zhang Z; Zeng C; Chang M; Xiao J; Wang J
    Biomed Chromatogr; 2011 Aug; 25(8):858-66. PubMed ID: 21728182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescribing amiodarone: an evidence-based review of clinical indications.
    Vassallo P; Trohman RG
    JAMA; 2007 Sep; 298(11):1312-22. PubMed ID: 17878423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing.
    Poirier JM; Escoubet B; Jaillon P; Coumel P; Richard MO; Cheymol G
    Eur J Drug Metab Pharmacokinet; 1988; 13(1):67-72. PubMed ID: 3396616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term treatment of ventricular tachycardia with amiodarone in presence of severe left ventricular dysfunction.
    Burckhardt D; Robertson A; Hoffmann A; Pfisterer M
    J Clin Pharmacol; 1991 Nov; 31(11):1105-8. PubMed ID: 1753016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Control of tachycardia with intravenous amiodarone in acute left heart failure].
    Tomcsányi J; Arabadzisz H; Zsoldos A; Marosi A; Beck K
    Orv Hetil; 2001 Dec; 142(52):2899-901. PubMed ID: 11828940
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers.
    Malesker MA; Mohiuddin SM; Destache CJ; Stoysich A; Dean RR; Hilleman DE; Sketch MH
    DICP; 1991 Mar; 25(3):231-4. PubMed ID: 2028626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials.
    Cadrin-Tourigny J; Wyse DG; Roy D; Blondeau L; Levesque S; Talajic M; Andrade JG; Dubuc M; Thibault B; Guerra PG; Macle L; Rivard L; Khairy P
    J Cardiovasc Electrophysiol; 2014 Dec; 25(12):1306-13. PubMed ID: 25181386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias.
    Nolan PE
    Pharmacotherapy; 1997; 17(2 Pt 2):65S-75S; discussion 89S-91S. PubMed ID: 9085342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias.
    Satomi K; Kurita T; Takatsuki S; Yokoyama Y; Chinushi M; Tsuboi N; Nitta T; Shoda M; Mitamura H
    Circ J; 2006 Aug; 70(8):977-84. PubMed ID: 16864928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Amiodarone administered orally or intravenously - the same or different drug?].
    Kosior DA; Krzykwa A; Postuła M
    Pol Merkur Lekarski; 2013 Apr; 34(202):183-7. PubMed ID: 23745321
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.